TAK · Takeda Pharmaceutical Company Limited

Takeda’s FY2026 results reflect a sharp rebound in profitability following a weak FY2025, with net profit attributable to owners more than doubling year-on-year. The improvement was underpinned by a 19.3% rise in operating profit—driven by disciplined cost management, including a 7.4% reduction in R&D spend and lower SG&A growth—despite a 1.7% revenue decline. That top-line contraction stemmed almost entirely from Neuroscience, where VYVANSE’s U.S. generic erosion continued to weigh, though growth across Gastroenterology, Rare Disease, Plasma-Derived Therapies, Oncology, and Vaccines partially offset it. Notably, non-core revenue fell 13.0%, reinforcing strategic focus on core franchises. Management attributes part of the earnings surge to favorable tax dynamics: income tax expense rose only 1.8% despite a 48.6% jump in pre-tax profit, yielding an effective tax rate of ~26.2%. Looking ahead, FY2027 guidance signals renewed pressure: while revenue is expected to grow 3.0%, net profit attributable to owners is projected to fall 13.4%, and Core Operating Profit is forecast to dip 1.1%. Critically, Constant Exchange Rate guidance implies even steeper underlying challenges—mid-teens Core EPS decline suggests meaningful margin compression, likely tied to anticipated commercial headwinds, ongoing investment in pipeline advancement, and persistent pricing pressures in key markets like the U.S. Dividend policy reflects confidence in cash generation: the per-share payout rose to JPY 200, yet the payout ratio dropped to 164.3% from 286.7%, confirming stronger earnings quality and sustainable capital return capacity. With operating cash flow remaining robust at JPY 1.04 trillion and balance sheet strength intact (50.3% equity-to-assets ratio), Takeda retains flexibility to fund R&D and strategic initiatives despite near-term earnings softness.